tiprankstipranks
Trending News
More News >

Beam Therapeutics sees cash runway into 2028

Beam expects that its cash, cash equivalents and marketable securities as of March 31, 2025, including net proceeds from the recent $500 million financing, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2028. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue